Related Experiment Video

Updated: Jul 9, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu

Marie P Piechocki1, Susan K Dibbley, Fulvio Lonardo

  • 1Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Center, Detroit, MI 48201, USA. piechock@karmanos.org

International Journal of Cancer
|December 14, 2007
PubMed

Insights

Gefitinib effectively prevented HER2/neu-mediated breast cancer in mice by inhibiting tumor development and signaling pathways. Early intervention with gefitinib is crucial for preventing HER2-driven cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2/neu overexpression drives breast cancer development.
  • Targeting HER2 signaling is a key strategy in breast cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of gefitinib in preventing HER2/neu-mediated breast cancer.
  • To investigate the effects of gefitinib on HER2 signaling pathways and immune responses.

Main Methods:

  • BALB-NeuT transgenic mice were treated orally with gefitinib from 5 to 14 weeks of age.
  • Tumor multiplicity, lobule development, and histopathology were assessed.
  • Phosphorylation of HER2/HER3, MAPK, and Akt signaling pathways were analyzed.
  • Immune responses in splenocytes and lymph nodes were evaluated.

Main Results:

  • Gefitinib reduced tumor multiplicity by 83% and decreased the size and number of lobules.
  • Normal mammary duct development was unaffected.
  • Gefitinib inhibited HER2/HER3 phosphorylation and downstream signaling (MAPK, Akt).
  • Immune responses, including MAPK activity and cytokine production, were increased in treated animals.

Conclusions:

  • Gefitinib is effective in preventing HER2/neu-driven breast cancer in a mouse model.
  • Early gefitinib treatment is critical for efficacy, with delayed treatment showing reduced effectiveness.
  • Targeting HER2 signal transduction is vital for preventing HER2-dependent breast cancer onset and progression.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...